SWP1001-06
14 Dec 2022
Trial Summary
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.
Acronym:
SWP1001-06
ACTRN/NCT /ethics:
NCT05198752
Scientific title:
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
Sponsor / Cooperative group:
Stemirna Therapeutics
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2022-03-18 |
| Anticipated End Date | 2024-06-12 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 8359 2565 |
| Principal Investigator | A/Prof Rohit Joshi |
| Recruitment Status | Recruiting |